Table 1. Characteristics of Patients With Hormone Receptor−Positive Endometrial Cancer, by Study Arm.
| Characteristic | No. (%) | |
|---|---|---|
| Vistusertib + anastrozole (n = 49) | Anastrozole (n = 24) | |
| Age, median (range), y | 70.8 (36.8-87.0) | 68.7 (40.5-87.8) |
| BMI | ||
| <25 | 15 (31) | 5 (21) |
| ≥25 and <30 | 15 (31) | 5 (21) |
| ≥30 | 19 (39) | 14 (58) |
| ECOG-PS | ||
| 0 | 26 (53) | 9 (38) |
| 1 | 23 (47) | 15 (63) |
| FIGO stage | ||
| III | 10 (20) | 4 (17) |
| IV | 39 (80) | 20 (83) |
| Endocrine receptors status | ||
| ER+ and PR+ | 36 (74) | 19 (83) |
| ER+ and PR– | 10 (20) | 3 (13) |
| ER– and PR+ | 3 (6) | 1 (4) |
| Grade | ||
| 1 | 10 (20) | 7 (29) |
| 2 | 17 (35) | 9 (38) |
| 3 | 12 (25) | 4 (17) |
| Unknown | 10 (20) | 4 (17) |
| Histologic subtype | ||
| Endometrioid | 43 (88) | 19 (79) |
| Other | 6 (12) | 5 (21) |
| Unknown | 1 (2) | 0 |
| Microsatellite status | ||
| Stable | 32 (65) | 15 (63) |
| Unstable | 13 (27) | 6 (25) |
| Unknown | 4 (8) | 3 (13) |
| Prior chemotherapy courses, No. | ||
| 0 | 22 (45) | 10 (42) |
| 1 | 27 (55) | 14 (58) |
| Prior endocrine therapy courses, No. | ||
| 0 | 42 (86) | 22 (92) |
| ≥1 | 7 (14) | 2 (8) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); ECOG-PS, Eastern Cooperative Oncology Group−performance status; ER, estrogen receptor; FIGO, International Federation of Gynecology and Obstetrics; PR, progesterone receptor.